Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis

Journal of Gastrointestinal Oncology

Volumn 8, Issue 1, 2017, Pages 164-172

  Borazanci, Erkut ^a   Millis, Sherri Z ^b   Kimbrough, Jeffery ^b   Doll, Nancy ^b   von Hoff, Daniel ^a   Ramanathan, Ramesh K ^c  

^a HonorHealth and the Scottsdale Lincoln Health Network   (United States)

^b CARIS LIFE SCIENCES   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Appendiceal cancer; Fluorescent in situ hybridization (FISH); Next generation sequencing (NGS)

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; ATM PROTEIN; B RAF KINASE; CYCLOOXYGENASE 2; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLTRANSFERASE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; O(6) METHYLGUANINE METHYLTRANSFERASE; OSTEONECTIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN DERIVATIVE; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M1; SMAD4 PROTEIN; THYMIDYLATE SYNTHASE; TRANSDUCIN LIKE ENHANCER OF SPLIT 3 PROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; APC GENE; APPENDIX CANCER; APPENDIX CARCINOMA; ARTICLE; ATM GENE; BRAF GENE; CANCER LOCALIZATION; CONTROLLED STUDY; FBXW7 GENE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL CARCINOID; GENE; GENE AMPLIFICATION; GENE SEQUENCE; GNAS GENE; GOBLET CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DIAGNOSIS; MUTATIONAL ANALYSIS; MYXOMA; NEUROENDOCRINE TUMOR; NEXT GENERATION SEQUENCING; ONCOGENE K RAS; PIK3CA GENE; PRIMARY TUMOR; PROTEIN EXPRESSION; SEX RATIO; SMAD4 GENE; VERY ELDERLY; YOUNG ADULT;

EID: 85014407094     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.21037/jgo.2017.01.14     Document Type: Article

References (28)

1. Connor SJ, Hanna GB, Frizelle FA. Appendiceal tumors: retrospective clinicopathologic analysis of appendiceal tumors from 7,970 appendectomies. Dis Colon Rectum 1998;41:75-80.
2. Esmer-Sánchez DD, Martínez-Ordaz JL, Román-Zepeda P, et al. Appendiceal tumors. Clinicopathologic review of 5,307 appendectomies. Cir Cir 2004;72:375-8.
3. Benedix F, Reimer A, Gastinger I, et al. Study Group Colon/Rectum Carcinoma Primary Tumor. Primary appendiceal carcinoma-epidemiology, surgery and survival: results of a German multi-center study. Eur J Surg Oncol 2010;36:763-71.
4. Turaga KK, Pappas SG, Gamblin T. Importance of histologic subtype in the staging of appendiceal tumors. Ann Surg Oncol 2012;19:1379-85.
5. Holt N, Grønbæk H. Goblet cell carcinoids of the appendix. ScientificWorldJournal 2013;2013:543696.
6. Tang LH. Epithelial neoplasms of the appendix. Arch Pathol Lab Med 2010;134:1612-20.
7. Pietrantonio F, Maggi C, Fanetti G, et al. FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist 2014;19:845-50.
8. Fornaro R, Frascio M, Sticchi C, et al. Appendectomy or right hemicolectomy in the treatment of appendiceal carcinoid tumors? Tumori 2007;93:587-90.
9. González-Moreno S, Sugarbaker PH. Right hemicolectomy does not confer a survival advantage in patients with mucinous carcinoma of the appendix and peritoneal seeding. Br J Surg 2004;91:304-11.
10. Turaga KK, Pappas S, Gamblin TC. Right hemicolectomy for mucinous adenocarcinoma of the appendix: just right or too much? Ann Surg Oncol 2013;20:1063-7.
11. Hata K, Tanaka N, Nomura Y, et al. Early appendiceal adenocarcinoma. A review of the literature with special reference to optimal surgical procedures. J Gastroenterol 2002;37:210-4.
12. Hinson FL, Ambrose NS. Pseudomyxoma peritonei. Br J Surg 1998;85:1332-9.
13. Hsu KH, Chou CY, Chang YC. Intraperitoneal hyperthermia in the management of pseudomyxoma peritonei. Hepatogastroenterology 2007;54:47-52.
14. Sugarbaker PH. Managing the peritoneal surface component of gastrointestinal cancer. Part 1. Patterns of dissemination and treatment options. Oncology (Williston Park) 2004;18:51-9.
15. Sugarbaker PH. Managing the peritoneal surface component of gastrointestinal cancer. Part 2. Perioperative intraperitoneal chemotherapy. Oncology (Williston Park) 2004;18:207-19.
16. Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas 2010;39:753-66.
17. Tejani MA, ter Veer A, Milne D, et al. Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer. J Natl Compr Canc Netw 2014;12:1123-30.
18. Liu X, Mody K, de Abreu FB, et al. Molecular profiling of appendiceal epithelial tumors using massively parallel sequencing to identify somatic mutations. Clin Chem 2014;60:1004-11.
19. Raghav KP, Shetty AV, Kazmi SM, et al. Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. Oncologist 2013;18:1270-7.
20. Millis SZ, Bryant D, Basu G, et al. Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. Clin Genitourin Cancer 2015;13:e37-49.
21. Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015;518:495-501.
22. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33:244-50.
23. Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997;17:79-83.
24. Fine RL, Gulati AP, Krantz BA, et al. Capecitabine and temozolomide (CAPTEM) for metastatic, welldifferentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol 2013;71:663-70.
25. Poynter JN,Haile RW, Siegmund KD, et al. Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev 2009;18:2745-50.
26. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015;372:2509-20
27. Perkins J, Boland P, Cohen SJ, et al. Successful imatinib therapy for neuroendocrine carcinoma with activating Kit mutation: a case study. J Natl Compr Canc Netw 2014;12:847-52.
28. Millis SZ, Arguello D, Lowery MA, et al. Multiplatform molecular profiling of 2,400 pancreatic adenocarcinomas to identify targets for therapeutic intent. J Clin Oncol 2014;32:abstr 4136.